Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nabil Adra

Showing results (21-30 of 96) with videos related to

Pageof 10
Sort By:
Investigational New Drugs|October 27, 2019
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinomaAnthony Wood, Saby George, Nabil Adra, et al.
Chinese Clinical Oncology|April 11, 2022
Literature review of management of brain metastases from germ cell tumorsAmy Le, Mona Arbab, Nabil Adra, et al.
Urologic Oncology|February 14, 2026
Clinical stage IIA/B embryonal carcinoma predominant nonseminomatous germ cell tumor: Minimizing treatment burdenJiping Zeng, Parth Thakker, Timothy A Masterson, et al.
Research Square|October 7, 2024
Measurement of Patients' Acceptable Symptom Levels and Priorities for Symptom Improvement in Advanced Prostate CancerStella Snyder, Ekin Secinti, Ellen Krueger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University ExperienceNabil Adra, Rafat Abonour, Sandra K Althouse, et al.
Urologic Oncology|February 12, 2022
Does pathological sub stratification of T2 bladder cancer predict outcome in a contemporary pure urothelial carcinoma cohort?Isamu Tachibana, Mohammad Mahmoud, Zain A Abedali, et al.
Urologic Oncology|July 23, 2020
Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?Isamu Tachibana, Elhaam Bandali, Adam C Calaway, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 4, 2026
Measurement of patients' acceptable symptom levels and priorities for symptom improvement in advanced prostate cancerStella Snyder, Ekin Secinti, Ellen F Krueger, et al.
Cancer Medicine|March 27, 2025
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial CarcinomaRoberto Pili, David I Quinn, Nabil Adra, et al.
JAMA Oncology|November 9, 2023
Outcomes in Patients With Postchemotherapy Residual Nonretroperitoneal Disease in Nonseminomatous Germ Cell TumorsJennifer King, Ryan Ashkar, Kenneth Kesler, et al.
Pageof 10

Showing results (21-30 of 96) with videos related to

Sort By:
Pageof 10
Investigational New Drugs|October 27, 2019
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinomaAnthony Wood, Saby George, Nabil Adra, et al.
Chinese Clinical Oncology|April 11, 2022
Literature review of management of brain metastases from germ cell tumorsAmy Le, Mona Arbab, Nabil Adra, et al.
Urologic Oncology|February 14, 2026
Clinical stage IIA/B embryonal carcinoma predominant nonseminomatous germ cell tumor: Minimizing treatment burdenJiping Zeng, Parth Thakker, Timothy A Masterson, et al.
Research Square|October 7, 2024
Measurement of Patients' Acceptable Symptom Levels and Priorities for Symptom Improvement in Advanced Prostate CancerStella Snyder, Ekin Secinti, Ellen Krueger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University ExperienceNabil Adra, Rafat Abonour, Sandra K Althouse, et al.
Urologic Oncology|February 12, 2022
Does pathological sub stratification of T2 bladder cancer predict outcome in a contemporary pure urothelial carcinoma cohort?Isamu Tachibana, Mohammad Mahmoud, Zain A Abedali, et al.
Urologic Oncology|July 23, 2020
Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?Isamu Tachibana, Elhaam Bandali, Adam C Calaway, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 4, 2026
Measurement of patients' acceptable symptom levels and priorities for symptom improvement in advanced prostate cancerStella Snyder, Ekin Secinti, Ellen F Krueger, et al.
Cancer Medicine|March 27, 2025
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial CarcinomaRoberto Pili, David I Quinn, Nabil Adra, et al.
JAMA Oncology|November 9, 2023
Outcomes in Patients With Postchemotherapy Residual Nonretroperitoneal Disease in Nonseminomatous Germ Cell TumorsJennifer King, Ryan Ashkar, Kenneth Kesler, et al.
Pageof 10